CN111358794A - 一种用于治疗非小细胞肺癌的药物或试剂盒 - Google Patents
一种用于治疗非小细胞肺癌的药物或试剂盒 Download PDFInfo
- Publication number
- CN111358794A CN111358794A CN202010173356.0A CN202010173356A CN111358794A CN 111358794 A CN111358794 A CN 111358794A CN 202010173356 A CN202010173356 A CN 202010173356A CN 111358794 A CN111358794 A CN 111358794A
- Authority
- CN
- China
- Prior art keywords
- inhibitor
- kras
- ars
- lung cancer
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 35
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title claims abstract description 24
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 title claims abstract description 24
- 229940079593 drug Drugs 0.000 title claims description 13
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 claims abstract description 41
- 239000003112 inhibitor Substances 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims abstract description 22
- 206010059866 Drug resistance Diseases 0.000 claims abstract description 20
- 229940125830 FGFR1 inhibitor Drugs 0.000 claims abstract description 20
- VRQMAABPASPXMW-HDICACEKSA-N AZD4547 Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3C[C@@H](C)N[C@@H](C)C3)C=2)=C1 VRQMAABPASPXMW-HDICACEKSA-N 0.000 claims abstract description 19
- 229940124647 MEK inhibitor Drugs 0.000 claims abstract description 18
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims abstract description 18
- 230000002147 killing effect Effects 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract 4
- 238000004113 cell culture Methods 0.000 claims description 11
- 102400000888 Cholecystokinin-8 Human genes 0.000 claims description 7
- 101800005151 Cholecystokinin-8 Proteins 0.000 claims description 7
- 238000002474 experimental method Methods 0.000 claims description 6
- 230000004663 cell proliferation Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229940126585 therapeutic drug Drugs 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 102000043136 MAP kinase family Human genes 0.000 description 6
- 108091054455 MAP kinase family Proteins 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 4
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 4
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 4
- 102100030708 GTPase KRas Human genes 0.000 description 4
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 4
- 238000011284 combination treatment Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 2
- 206010064571 Gene mutation Diseases 0.000 description 2
- 101150105104 Kras gene Proteins 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 101150016624 fgfr1 gene Proteins 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 102200006538 rs121913530 Human genes 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开KRASG12C抑制剂和FGFR1抑制剂的联合使用在制备治疗非小细胞肺癌药物或试剂盒方面的应用；本发明还公开KRASG12C抑制剂和MEK抑制剂的联合使用在制备治疗非小细胞肺癌药物或试剂盒方面的应用；本发明还公开一种用于治疗非小细胞肺癌的药物或试剂盒，包括KRASG12C抑制剂ARS‑1620、及与KRASG12C抑制剂ARS‑1620联合使用的FGFR1抑制剂AZD4547或MEK抑制剂PD032590中的一种。本发明联合使用ARS‑1620和FGFR1抑制剂AZD4547，或联合使用ARS‑1620和MEK抑制剂PD032590，均能显著增强杀伤作用，而且能够抑制耐药产生，为非小细胞肺癌的治疗提供有效的治疗药物和治疗方向。
Description
技术领域
本发明属于生物医疗技术领域，具体涉及一种用于治疗非小细胞肺癌的药物或试剂盒。
背景技术
肺癌中大多数为非小细胞肺癌(NSCLC)，其中约30％的患者携带促癌的KRAS基因突变。KRAS基因突变最常见类型是第12位氨基酸G→C突变(KRASG12C)，该突变导致肺癌的分子机制是过度激活了MAPK信号通路(即KRAS/RAF/MEK/ERK级联信号通路)。体外研究发现，KRASG12C抑制剂虽然可以特异性杀伤KRASG12C的肺癌细胞株，但效果维持时间短，细胞能快速产生耐药。目前尚缺乏高效特异的方法或药物来杀伤KRASG12C细胞，同时能够抑制耐药的出现。
发明内容
本发明要解决的技术问题是提供用于治疗非小细胞肺癌的药物或试剂盒，能够抑制耐药的出现，以解决背景技术中所提出的问题。
本发明的实施例提供KRASG12C抑制剂和FGFR1抑制剂的联合使用在制备治疗非小细胞肺癌药物或试剂盒方面的应用。
进一步的，所述KRASG12C抑制剂为ARS-1620。
进一步的，所述FGFR1抑制剂为AZD4547。
本发明的实施例还提供KRASG12C抑制剂和MEK抑制剂联合使用在制备治疗非小细胞肺癌药物或试剂盒方面的应用。
其中，所述KRASG12C抑制剂为ARS-1620。
其中，所述MEK抑制剂为PD032590。
本发明的实施例还提供一种用于治疗非小细胞肺癌的药物，其特征在于，包括KRASG12C抑制剂ARS-1620、与KRASG12C抑制剂ARS-1620联合使用的FGFR1抑制剂AZD4547或MEK抑制剂PD032590中的一种。
本发明的实施例还一种用于治疗非小细胞肺癌的试剂盒，其特征在于，包括KRASG12C抑制剂ARS-1620、与KRASG12C抑制剂ARS-1620联合使用的FGFR1抑制剂AZD4547或MEK抑制剂PD032590中的一种。
本发明的实施例另外还提供一种用于治疗非小细胞肺癌的药物或试剂盒的耐药性的检测方法，其特征在于，具体包括以下步骤：
(1)在96孔细胞培养板中培养携带KRASG12C突变的细胞株H23，Calu-1，H358；
(2)在步骤(1)所制备完成的96孔细胞培养板中，使用FGFR1抑制剂AZD4547单独进行处理103H358-P或H358-R细胞；72小时后用CCK8细胞增殖实验检测对细胞的杀伤作用，然后持续用药，观察耐药出现的时间；
(3)在步骤(1)所制备完成的96孔细胞培养板中，用1μM FGFR1抑制剂AZD4547与1μM的ARS-1620联合使用或100nM MEK抑制剂PD032590与100nM的ARS-1620联合使用进行处理103H358-P或H358-R细胞，72小时后用CCK8细胞增殖实验检测对细胞的杀伤作用，然后持续用药，观察耐药出现的时间；
(4)比较步骤(2)和步骤(3)中耐药出现的时间，从而验证试剂盒的耐药性。
本发明的上述技术方案的有益效果如下：本发明针对KRASG12C抑制剂ARS-1620对敏感细胞只有短暂的抑制作用，很容易诱导耐药的问题，研究了耐药的机制介导，可以发现由以下两个机制介导：FGFR1基因高表达或MAPK信号通路重激活；因此，本发明联合使用ARS-1620和FGFR1抑制剂AZD4547，或联合使用ARS-1620和MEK抑制剂PD032590，均能显著增强杀伤作用，而且能够抑制耐药产生，为非小细胞肺癌的治疗提供有效的治疗药物和治疗方向。
附图说明
图1为本发明中的实施例1中使用1μM ARS-1620处理Calu-1、H23、H358细胞，72h后检测细胞的存活率情况图；
图2为本发明中的实施例1中FGFR1在H358-P和H358-R中的表达情况图；
图3为本发明中的实施例1中1μM ARS-1620和1μM AZD4547联合处理H358-P和H358-R细胞，72h后检测存活率情况图；
图4为本发明中的实施例2中1μM ARS-1620处理H358细胞不同时间后，检测ERK,p-ERK和内参Vinculin的表达图；其中，p-ERK的表达水平代表了MAPK信号通路的激活程度；
图5为本发明中的实施例2中100nM ARS-1620和100nM PD0325901联合处理H358-P和H358-R细胞，72h后检测存活率图。
具体实施方式
为使本发明要解决的技术问题、技术方案和优点更加清楚，下面将结合附图及具体实施例进行详细描述。
一、本发明的实施例中所用实验材料来源：
ARS-162购自美国Selleck公司，货号S8707；
AZD4547购自美国Selleck公司，货号S2801；
PD0325901购自美国MCE公司,货号HY-10254；
H23,Calu-1和H358肺癌细胞株均购自美国ATCC公司(American Type CultureCollection)公司，南通大学医学院免疫学系保存。
二、本发明分别在多个96孔细胞培养板中培养携带KRASG12C突变的细胞株H23,Calu-1,H358，便于以下实施例中实验的操作。
实施例一
ARS-1620和AZD4547联合处理、效果分析：
(1)KRASG12C抑制剂ARS-1620处理
(1-1)在96孔细胞培养板中，用1μM的KRASG12C抑制剂ARS-1620处理103细胞(104/ml)，72小时后CCK8细胞增殖实验方法检测细胞对药物的敏感性，获得最敏感细胞株H358作为细胞模型(图1)。
(1-2)继续用1μM的KRASG12C抑制剂ARS-1620处理H358细胞2周，期间每2天换液去除死细胞，2周后细胞恢复增殖速度，获得ARS-1620耐受的H358细胞(H358-R)。
(1-3)收集2×106未处理的亲本的H358细胞(H358-P)和2×106H358-R细胞，用Trizol法提取细胞的RNA，然后用RNA测序的方法获得转录组数据，其中包含了细胞内所有基因的表达水平，结果显示3421个基因在H358-R中比H358-P中表达升高，2723个基因表达下降。
(1-4)仔细分析H358-P和H358-R的转录组，发现在升高的基因中，FGFR1的表达增加特别显著(如图2所示)，提示FGFR1可能是诱导耐药的关键因素。
(2)1μM FGFR1抑制剂AZD4547和1μM的ARS-1620同时处理
(2-1)在96孔细胞培养板中，用1μM FGFR1抑制剂AZD4547和1μM的ARS-1620同时处理103H358-P或H358-R细胞(104/ml)，72小时后用CCK8细胞增殖实验检测对细胞的杀伤作用。
(3)结果分析
结果证实H358-R细胞完全耐受双药的联合处理，但H358-P对双药联合处理极其敏感(如图3所示)，而且培养4周没有耐药，这与ARS-1620单药后快速出现耐药形成显著对比。
实施例二
(4)ARS-1620和PD0325901联合使用、效果分析：
在96孔细胞培养板中，用1μM ARS-1620处理2×106H358细胞6小时，12小时，24小时，48小时，18天，42天，用Western blot分析MAPK信号通路，发现耐药的细胞(D18,D42)的p-ERK显著增加，提示MAPK信号通路增强(如图4所示)。
在96孔细胞培养板中，用100nM MEK抑制剂PD0325901(抑制MAPK通路)和100nM的ARS-1620同时处理1×103H358-P或H358-R细胞(104/ml)，72小时后用CCK8细胞增殖实验检测药物对细胞的杀伤作用。
结果证实H358-R细胞完全耐受双药的联合处理，但H358-P对双药处理极其敏感(如图5所示)，而且培养4周没有耐药，这与ARS-1620单药后快速出现耐药形成显著对比。
更进一步的，本发明提出对于敏感的细胞先用ARS-1620单药处理，一旦耐药，对ARS-1620和FGFR1抑制剂AZD4547，ARS-1620和MEK抑制剂PD032590联合处理也耐药，因此，本发明提出对敏感的细胞必须直接采取联合处理。
以上所述是本发明的优选实施方式，应当指出，对于本技术领域的普通技术人员来说，在不脱离本发明所述原理的前提下，还可以作出若干改进和润饰，这些改进和润饰也应视为本发明的保护范围。
Claims (9)
1.KRASG12C抑制剂和FGFR1抑制剂的联合使用在制备治疗非小细胞肺癌药物或试剂盒方面的应用。
2.根据权利要求1所述的KRASG12C抑制剂和FGFR1抑制剂的联合使用在制备治疗非小细胞肺癌药物或试剂盒方面的应用，其特征在于，所述KRASG12C抑制剂为ARS-1620。
3.根据权利要求1所述的KRASG12C抑制剂和FGFR1抑制剂的联合使用在制备治疗非小细胞肺癌药物或试剂盒方面的应用，其特征在于，所述FGFR1抑制剂为AZD4547。
4.KRASG12C抑制剂和MEK抑制剂联合使用在制备治疗非小细胞肺癌药物或试剂盒方面的应用。
5.根据权利要求4所述的KRASG12C抑制剂和MEK抑制剂的联合使用在制备治疗非小细胞肺癌药物或试剂盒方面的应用，其特征在于，所述KRASG12C抑制剂为ARS-1620。
6.根据权利要求4所述的KRASG12C抑制剂和MEK抑制剂的联合使用在制备治疗非小细胞肺癌药物或试剂盒方面的应用，其特征在于，所述MEK抑制剂为PD032590。
7.一种用于治疗非小细胞肺癌的药物，其特征在于，包括KRASG12C抑制剂ARS-1620、与KRASG12C抑制剂ARS-1620联合使用的FGFR1抑制剂AZD4547或MEK抑制剂PD032590中的一种。
8.一种用于治疗非小细胞肺癌的试剂盒，其特征在于，包括KRASG12C抑制剂ARS-1620、与KRASG12C抑制剂ARS-1620联合使用的FGFR1抑制剂AZD4547或MEK抑制剂PD032590中的一种。
9.一种根据权利要求7或8所述的用于治疗非小细胞肺癌的药物或试剂盒的耐药性的检测方法，其特征在于，具体包括以下步骤：
(1)在96孔细胞培养板中培养携带KRASG12C突变的细胞株H23，Calu-1，H358；
(2)在步骤(1)所制备完成的96孔细胞培养板中，使用FGFR1抑制剂AZD4547单独进行处理103H358-P或H358-R细胞；72小时后用CCK8细胞增殖实验检测对细胞的杀伤作用，然后持续用药，观察耐药出现的时间；
(3)在步骤(1)所制备完成的96孔细胞培养板中，用1μM FGFR1抑制剂AZD4547与1μM的ARS-1620联合使用或100nM MEK抑制剂PD032590与100nM的ARS-1620联合使用进行处理103H358-P或H358-R细胞，72小时后用CCK8细胞增殖实验检测对细胞的杀伤作用，然后持续用药，观察耐药出现的时间；
(4)比较步骤(2)和步骤(3)中耐药出现的时间，从而验证药物或试剂盒的耐药性。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010173356.0A CN111358794A (zh) | 2020-03-13 | 2020-03-13 | 一种用于治疗非小细胞肺癌的药物或试剂盒 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010173356.0A CN111358794A (zh) | 2020-03-13 | 2020-03-13 | 一种用于治疗非小细胞肺癌的药物或试剂盒 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111358794A true CN111358794A (zh) | 2020-07-03 |
Family
ID=71199440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010173356.0A Pending CN111358794A (zh) | 2020-03-13 | 2020-03-13 | 一种用于治疗非小细胞肺癌的药物或试剂盒 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111358794A (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113304147A (zh) * | 2021-05-13 | 2021-08-27 | 南通大学 | Hsp90抑制剂在治疗耐药性kras突变肺癌方面的应用 |
| WO2022119349A1 (ko) * | 2020-12-04 | 2022-06-09 | 울산대학교 산학협력단 | Kras 억제제에 대한 내성 억제용 조성물 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016044772A1 (en) * | 2014-09-18 | 2016-03-24 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
| WO2018119183A2 (en) * | 2016-12-22 | 2018-06-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| CN108452310A (zh) * | 2017-02-17 | 2018-08-28 | 四川大学华西医院 | 一种治疗肿瘤的联合用药物 |
| CN110664818A (zh) * | 2019-10-14 | 2020-01-10 | 暨南大学 | 一种治疗肺癌的药物 |
-
2020
- 2020-03-13 CN CN202010173356.0A patent/CN111358794A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016044772A1 (en) * | 2014-09-18 | 2016-03-24 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
| WO2018119183A2 (en) * | 2016-12-22 | 2018-06-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| CN108452310A (zh) * | 2017-02-17 | 2018-08-28 | 四川大学华西医院 | 一种治疗肿瘤的联合用药物 |
| CN110664818A (zh) * | 2019-10-14 | 2020-01-10 | 暨南大学 | 一种治疗肺癌的药物 |
Non-Patent Citations (2)
| Title |
|---|
| KEVIN LOU等: "KRASG12C inhibition produces a driver-limited state revealing collateral dependencies", 《SCI SIGNAL.》 * |
| 梁毅舟: "青蒿琥酯对人唾液腺腺样囊性癌耐药细胞系SACC-83/DDP抑制及耐药逆转作用的研究", 《万方学位论文》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022119349A1 (ko) * | 2020-12-04 | 2022-06-09 | 울산대학교 산학협력단 | Kras 억제제에 대한 내성 억제용 조성물 |
| CN113304147A (zh) * | 2021-05-13 | 2021-08-27 | 南通大学 | Hsp90抑制剂在治疗耐药性kras突变肺癌方面的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yin et al. | Transglutaminase 2 inhibition reverses mesenchymal transdifferentiation of glioma stem cells by regulating C/EBPβ signaling | |
| CN111358794A (zh) | 一种用于治疗非小细胞肺癌的药物或试剂盒 | |
| Li et al. | Fatty liver mediated by peroxisome proliferator‐activated receptor‐α DNA methylation can be reversed by a methylation inhibitor and curcumin | |
| Nie et al. | miR‐331‐3p inhibits inflammatory response after intracerebral hemorrhage by directly targeting NLRP6 | |
| Cheng et al. | Snail-regulated exosomal microRNA-21 suppresses NLRP3 inflammasome activity to enhance cisplatin resistance | |
| Li et al. | Triterpenoid ursolic acid drives metabolic rewiring and epigenetic reprogramming in treatment/prevention of human prostate cancer | |
| Du et al. | Comparative analysis of the immune responses in cancer cells irradiated with X-ray, proton and carbon-ion beams | |
| Chen et al. | A potential circRNA-miRNA-mRNA regulatory network in asthmatic airway epithelial cells identified by integrated analysis of microarray datasets | |
| Wang et al. | Differential expression profiles of lncRNA following LPS-induced inflammation in bovine mammary epithelial cells | |
| Noureddine et al. | microRNA-449a reduces growth hormone-stimulated senescent cell burden through PI3K-mTOR signaling | |
| JP2022547105A (ja) | オフターゲット評価に基づく遺伝子編集治療の評価方法 | |
| CN112843038B (zh) | 一种药物在制备治疗弥漫大b细胞淋巴瘤药物中的应用 | |
| Ma et al. | [Retracted] Efficacy of Crizotinib Combined with Chemotherapy in Treating Advanced Non‐Small‐Cell Lung Cancer and Effect on Patients’ Quality of Life and Adverse Reaction Rate | |
| Lu et al. | Remodels the Immunosuppressive Tumor Microenvironment by Combination of Bacillus Calmette–Guérin and Anti-PD-L1 in an Orthotopic Triple-Negative Breast Cancer Mouse Model | |
| Yong-Jiea et al. | STAT3 Inhibition by Centipede Scolopendra Extract in Liver Cancer HepG2 Cells and Orthotopic Mouse Models of Hepatocellular Carcinoma | |
| Sun et al. | Bioinformatics analysis reveals potential candidate drugs for psychological stress in ovarian cancer. | |
| Turk et al. | NK-cell dysfunction of acute myeloid leukemia in relation to the renin–angiotensin system and neurotransmitter genes | |
| CN111467332B (zh) | 低温等离子体与二甲双胍联用的应用 | |
| Andrade | The role of Epigenetics in Glioblastoma-A Meta Analysis | |
| CN107354159A (zh) | 长链非编码RNA SMAD5‑AS1的siRNA在卵巢癌治疗中的应用 | |
| CN113244240A (zh) | 醋酸巴多昔芬在治疗急性髓系白血病药物中的应用 | |
| Han-Ying et al. | Snail-regulated exosomal microRNA-21 suppresses NLRP3 inflammasome activity to enhance cisplatin resistance | |
| Zhang et al. | Identification of key genes and signaling pathways in male androgenetic alopecia by bioinformatics analysis | |
| Samal et al. | Emerging Transcriptomic Approaches to Decipher Mycobacterial Complexities | |
| Lechtenberg | Igniting Inflammation: Microglia are Pro-Inflammatory First Responders After Ischemic Stroke |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200703 |
|
| RJ01 | Rejection of invention patent application after publication |